120281-22-3Relevant academic research and scientific papers
Discovery of cyclopropyl chromane-derived pyridopyrazine-1,6-dione γ-secretase modulators with robust central efficacy
Pettersson, Martin,Johnson, Douglas S.,Rankic, Danica A.,Kauffman, Gregory W.,Am Ende, Christopher W.,Butler, Todd W.,Boscoe, Brian,Evrard, Edelweiss,Helal, Christopher J.,Humphrey, John M.,Stepan, Antonia F.,Stiff, Cory M.,Yang, Eddie,Xie, Longfei,Bales, Kelly R.,Hajos-Korcsok, Eva,Jenkinson, Stephen,Pettersen, Betty,Pustilnik, Leslie R.,Ramirez, David S.,Steyn, Stefanus J.,Wood, Kathleen M.,Verhoest, Patrick R.
supporting information, p. 730 - 743 (2017/04/27)
Herein we describe the discovery of a novel series of cyclopropyl chromane-derived pyridopyrazine-1,6-dione γ-secretase modulators for the treatment of Alzheimer's disease (AD). Using ligand-based design tactics such as conformational analysis and molecul
Mild synthesis of sterically congested alkyl aryl ethers
Lindstedt, Erik,Stridfeldt, Elin,Olofsson, Berit
, p. 4234 - 4237 (2016/09/09)
An efficient and transition-metal-free method is presented to access tertiary alkyl aryl ethers by arylation of tertiary alcohols with ortho-substituted diaryliodonium salts. The scope covers cyclic and acyclic aliphatic, benzylic, allylic, and propargyli
CHROMENE AND 1,1 A,2,7B-TETRAHYDROCYCLOPROPA[C]CHROMENE PYRIDOPYRAZINEDIONES AS GAMMA-SECRETASE MODULATORS
-
Page/Page column 67; 68; 70; 71, (2015/12/30)
Compounds and pharmaceutically acceptable salts of the compounds are disclosed, wherein the compounds have the structure of Formula (I), wherein X, R1, R2a, R2b, R4a, R4b, R5a, R5b/su
ARYL AND HETEROARYL ETHER COMPOUNDS AS ROR GAMMA MODULATORS
-
Page/Page column 100; 105, (2015/11/09)
The present disclosure is directed to compounds of formula (I) and pharmaceutically acceptable salts thereof, wherein Ring A, Ring B, R, R2, R3, n, and p are as defined herein, which are active as modulators of retinoid-related orpha
Variation in the aromatic ring of cromakalim: Antihypertensive activity of pyranopyridines and 6-alkyl-2H-1-benzopyrans
Burrell,Cassidy,Evans,Lightowler,Stemp
, p. 3023 - 3027 (2007/10/02)
The synthesis and antihypertensive activity in the spontaneously hypertensive rat of two new series of analogues related to cromakalim (1) are described. In the first series, where the benzopyran nucleus has been replaced by a pyranopyridine nucleus, the
Benzopyran derivatives
-
, (2008/06/13)
Compounds of the formula STR1 wherein R 1 is hydrogen, halogen, trifluoromethyl, nitro, cyano, lower alkyl, lower alkoxycarbonyl, lower alkylthio, lower alkylsulphonyl, lower alkanoyl, aroyl, carbamoyl, mono(lower alkyl)carbamoyl or di(lower alkyl)carbamoyl, R 2 is hydrogen, lower alkyl or phenyl, R 3 is hydrogen or lower alkyl, R 4 and R 5 each is hydrogen or R 4 is hydroxy and R 5 is hydrogen or R 4 and R 5 together are a carbon-carbon bond and R 6 is an aryl or N-heteroaryl group carrying a hydroxy group in the 2-position or, in the case of a N-heteroaryl group, also a N-oxide group in the 2-position, and pharmaceutically acceptable acid addition salts of these compounds of formula I which are basic, possess pronounced potassium channel activating activity and can be used as medicaments, particularly in the control or prevention of hypertension, congestive heart failure, angina pectoris, peripheral and cerebral vascular disease and smooth muscle disorders.
